Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis
Nefropatía membranosa muy tardía secundaria a alemtuzumab en paciente con esclerosis múltiple
Área salud
Impact of the COVID-19 pandemic on the physical activity habits of people with multiple sclerosis in Spain
Background According to the literature, patients with multiple sclerosis (MS) are less active and show higher levels of sedentary behaviour than the general population of the same age range. This study aims to explore the […]
Área salud
Inicio temprano de alemtuzumab: cambio en el paradigma de tratamiento en esclerosis múltiple. Análisis intermedio del estudio LEMVIDA
Introducción LEMVIDA es un estudio de práctica clínica, prospectivo, de tres años de seguimiento sobre calidad de vida en pacientes con esclerosis múltiple (EM) tratados con alemtuzumab en España. Métodos Análisis intermedio de las características […]
Área salud
Prevalence study of multiple sclerosis in the Spanish province of Zamora
Introduction We conducted a prevalence study of multiple sclerosis (MS) in the Spanish province of Zamora. Methods We conducted a retrospective cohort study of data on patients with multiple sclerosis under follow-up at the neurology […]